Seth Levy, MD
Internal Medicine · Denville, NJNPI 1316980782
Payments from drug & device makers
Across 123 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$412
- Pfizer$308
- Novo Nordisk$235
- Axsome Therapeutics, Inc.$121
- Baxter Healthcare$118
- Lilly USA, LLC$115
- plus $987 from 25 others
What the payments were for
- Food & beverage$2,296100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 27 | $412 |
| Pfizer | 20 | $308 |
| Novo Nordisk | 14 | $235 |
| Axsome Therapeutics, Inc. | 1 | $121 |
| Baxter Healthcare | 1 | $118 |
| Lilly USA, LLC | 7 | $115 |
| Boehringer Ingelheim | 6 | $98 |
| AstraZeneca | 6 | $90 |
| GSK | 5 | $87 |
| Merck | 4 | $66 |
| BD | 2 | $58 |
| Abbott | 3 | $57 |
| Sanofi Pasteur Inc. | 3 | $55 |
| IBSA Pharma Inc. | 3 | $50 |
| Johnson & Johnson | 1 | $44 |
| Astellas Pharma US Inc | 2 | $43 |
| Alk-abello, Inc | 2 | $40 |
| Lundbeck LLC | 2 | $39 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
| Exact Sciences | 1 | $29 |
| W. L. Gore & Associates, Inc. | 1 | $28 |
| Medtronic | 1 | $22 |
| Novartis | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Seqirus USA Inc | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Cumberland Pharmaceuticals, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Amgen | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Symbravo$121
- Renal - PD$118
How this compares
$2,296 in reported general payments places this provider in the 75th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 114 | $108,825 |
| OzempicSemaglutide | 78 | $92,184 |
| JardianceEmpagliflozin | 57 | $82,162 |
| MounjaroTirzepatide | 54 | $68,316 |
| XareltoRivaroxaban | 48 | $48,741 |
| FarxigaDapagliflozin Propanediol | 37 | $42,700 |
| JanuviaSitagliptin Phosphate | 33 | $30,826 |
| TradjentaLinagliptin | 19 | $28,708 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $23,781 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $20,792 |
| TrulicityDulaglutide | 18 | $18,524 |
| MyrbetriqMirabegron | 21 | $17,973 |
| DiovanValsartan | 13 | $14,938 |
| Lagevrio (Eua)Molnupiravir | 17 | $13,793 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $9,913 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $98 | $110,87176 claims |
| PfizerEliquis | $308 | $108,825114 claims |
| Novo NordiskOzempic | $235 | $92,18478 claims |
| Lilly USA, LLCMounjaro, Trulicity | $115 | $86,84072 claims |
| MerckJanuvia, Janumet, Lagevrio (Eua) | $66 | $68,40165 claims |
| Johnson & JohnsonXarelto | $44 | $48,74148 claims |
| AstraZenecaFarxiga | $90 | $42,70037 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $87 | $30,70529 claims |
| Astellas Pharma US IncMyrbetriq | $43 | $17,97321 claims |
| NovartisDiovan | $19 | $14,93813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Denville
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.